textabstractIn the 19th century, age-related maculopathy (ARM) was described for the first time as an agerelated abnormality of the macula lutea. ARM consists of a variety of clinical signs, from the early stages with soft distinct drusen, indistinct drusen and pigment alterations up to the late stages of geographic atrophy and neovascular macular degeneration. These late stages are also referred to as age-related macular degeneration. Nowadays, ARM is the leading cause of blindness among the elderly in the Western world. With the rapidly growing popUlation of the elderly, it can be estimated that in the Netherlands ahnost 115,000 people will have signs of the end stages in the year 2030. This will have great implications for the quality o...
textabstractWhat’s in a name? Since the first description of age-related macular degeneration in 18...
AIM: Age-related macular degeneration (AMD) is a common macular disease in the developed world and r...
Contains fulltext : 138083.pdf (publisher's version ) (Open Access)PURPOSE: We stu...
textabstractThe western world is aging rapidly. In the Netherlands, the current mean life expectanc...
textabstractIn 1875, Pagenstecher and Gentll provided the first description of age-related maculopat...
textabstractAge-related maculopathy (ARM) is an age-related degenerative disorder of the central par...
Age-related maculopathy (ARM) is the leading cause of blindness in the elderly. Although beneficial ...
Age-related maculopathy (ARM) has remained a challenging topic with respect to its aetiology, pathom...
Stephen G Schwartz,1 Blake M Hampton,1 Jaclyn L Kovach,1 Milam A Brantley Jr2 1Department of Ophtha...
Age-related maculopathy (ARM) is a leading cause of permanent vision loss in elderly people. ARM the...
Age-related macular degeneration (AMD) is a chronic degenerative disease of the central retina and a...
Age-related macular degeneration (AMD) is a common condition among the elderly population that leads...
Age-related macular degeneration (AMD) is a common condition among the elderly population that leads...
AIM: Age-related macular degeneration (AMD) is a common macular disease in the developed world and r...
Age-related macular degeneration (AMD) is a common condition among the elderly population that leads...
textabstractWhat’s in a name? Since the first description of age-related macular degeneration in 18...
AIM: Age-related macular degeneration (AMD) is a common macular disease in the developed world and r...
Contains fulltext : 138083.pdf (publisher's version ) (Open Access)PURPOSE: We stu...
textabstractThe western world is aging rapidly. In the Netherlands, the current mean life expectanc...
textabstractIn 1875, Pagenstecher and Gentll provided the first description of age-related maculopat...
textabstractAge-related maculopathy (ARM) is an age-related degenerative disorder of the central par...
Age-related maculopathy (ARM) is the leading cause of blindness in the elderly. Although beneficial ...
Age-related maculopathy (ARM) has remained a challenging topic with respect to its aetiology, pathom...
Stephen G Schwartz,1 Blake M Hampton,1 Jaclyn L Kovach,1 Milam A Brantley Jr2 1Department of Ophtha...
Age-related maculopathy (ARM) is a leading cause of permanent vision loss in elderly people. ARM the...
Age-related macular degeneration (AMD) is a chronic degenerative disease of the central retina and a...
Age-related macular degeneration (AMD) is a common condition among the elderly population that leads...
Age-related macular degeneration (AMD) is a common condition among the elderly population that leads...
AIM: Age-related macular degeneration (AMD) is a common macular disease in the developed world and r...
Age-related macular degeneration (AMD) is a common condition among the elderly population that leads...
textabstractWhat’s in a name? Since the first description of age-related macular degeneration in 18...
AIM: Age-related macular degeneration (AMD) is a common macular disease in the developed world and r...
Contains fulltext : 138083.pdf (publisher's version ) (Open Access)PURPOSE: We stu...